5,831,813 Shares in Compass Therapeutics, Inc. $CMPX Bought by Palo Alto Investors LP

Palo Alto Investors LP bought a new position in Compass Therapeutics, Inc. (NASDAQ:CMPX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,831,813 shares of the company’s stock, valued at approximately $12,771,670. Compass Therapeutics comprises about 0.0% of Palo Alto Investors LP’s investment portfolio, making the stock its 19th biggest position. Palo Alto Investors LP owned approximately 3.24% of Compass Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of CMPX. Strs Ohio purchased a new position in Compass Therapeutics during the 1st quarter worth approximately $34,000. Creative Planning bought a new stake in shares of Compass Therapeutics in the 2nd quarter worth about $30,000. XTX Topco Ltd bought a new stake in shares of Compass Therapeutics in the 2nd quarter worth $84,000. Invesco Ltd. lifted its holdings in shares of Compass Therapeutics by 58.1% during the 2nd quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock valued at $153,000 after buying an additional 21,578 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. lifted its holdings in shares of Compass Therapeutics by 11.3% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock worth $11,505,000 after acquiring an additional 449,868 shares during the period. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Trading Down 4.8%

CMPX traded down $0.12 during trading on Friday, reaching $2.40. The stock had a trading volume of 2,565,185 shares, compared to its average volume of 4,559,978. The company has a market capitalization of $432.21 million, a price-to-earnings ratio of -6.00 and a beta of 0.92. The stock’s 50 day moving average is $2.18 and its two-hundred day moving average is $3.47. Compass Therapeutics, Inc. has a one year low of $1.61 and a one year high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). On average, equities research analysts predict that Compass Therapeutics, Inc. will post -0.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

CMPX has been the subject of several research reports. Citigroup reissued a “market outperform” rating on shares of Compass Therapeutics in a research note on Thursday, June 4th. Wall Street Zen lowered Compass Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 8th. Piper Sandler raised their price objective on shares of Compass Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a report on Friday, July 17th. Finally, LADENBURG THALM/SH SH assumed coverage on Compass Therapeutics in a report on Wednesday, July 1st. They set a “buy” rating and a $5.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $11.77.

Compass Therapeutics Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.